We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Notably, Merck's Winrevair pulmonary arterial hypertension (PAH) medication is on track to be the company's next blockbuster drug, already delivering $419 million in sales in just the first two ...

Great investments are even better and more fruitful when you can buy them at a discount. Lots of investors enjoy keeping an ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

In the third quarter, Merck reported a decline of 11% in Gardasil sales to $2.31 billion. The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales ...

Merck reported adjusted earnings of $1.72 per ... to $15.62 billion driven by Keytruda, new products like Winrevair and strong performance of the Animal Health segment, partially offset by lower ...

Medicare Part D redesign is expected to hurt sales by approximately $400 million, primarily affecting Winrevair and oncology products, including Welireg, Lynparza and Lenvima. Merck expects top ...